PubMed Health⌕ Search

Biomedical subjects

R Palchetti

Publications and source records attributed to R Palchetti.

At least 19 recordsLinked to original sources

Possible association between eosinophilic fasciitis and subcutaneous heparin use.

The association between the onset of eosinophilic fasciitis and exposure to a drug or a toxin has occasionally been reported. We describe 3 patients who developed eosinophilic fasciitis a few months after they received subcutaneous calcium heparin. In 2 patients, clinical manifestations and eosinophilia improved after interruption of the therapy. Although spontaneous occurrence of eosinophilic fasciitis cannot be excluded in our patients, the temporal relationship with the beginning of subcutaneous heparin therapy raises the possibility that the syndrome might be precipitated by the drug.

Adult↗

[Pharmacological cardioversion of isolated atrial fibrillation: recovery of atrial mechanical function and correlation with duration of arrhythmia].

To evaluate how the duration of atrial fibrillation before cardioversion affects the recovery of atrial systolic function, serial transthoracic pulsed Doppler echocardiographic studies were performed within 2 hours and at 2 days, 7 days, 1 month and 2 months after chemical cardioversion to sinus rhythm. Peak A wave velocity (A), velocity time integral of A wave (A-VTI) and percent A-wave filling (A/VTI-tot) were assessed in 60 patients with lone atrial fibrillation of brief (> or = 12 to < or = 72 hours, 20 patients), moderate (> 72 hours to < or = 4 weeks, 20 patients) or prolonged (> 4 to < or = 24 weeks, 20 patients) duration. The three groups were well matched for age and left atrial size and none of the patients underwent antiarrhythmic therapy during follow-up. Atrial mechanical function is greater immediately and at 2 and 7 days after cardioversion in patients with brief atrial fibrillation, as compared moderate and prolonged atrial fibrillation (A and A/VTI-tot values: p < 0.05, p < 0.005 and p < 0.05, respectively). In addition, at 7 days after cardioversion, atrial systolic function is greater in patients with moderate atrial fibrillation as compared to prolonged atrial fibrillation (A value, p < 0.005 and A/VTI-tot value, p < 0.05). In all groups, atrial mechanical function increases over time and ultimately achieves similar levels. Full recovery of atrial mechanical function is achieved within 2 days in patients with brief atrial fibrillation, within 7 days in patients with atrial fibrillation of moderate duration and within 1 month in patients with prolonged atrial fibrillation. Recovery of the mechanical function of the left atrium is related to the duration of atrial fibrillation before cardioversion. These findings have important implications for assessing the early hemodynamic benefits of successful cardioversion.

Adult↗

[Propafenone and sotalol: long-term efficacy and tolerability in the prevention of paroxysmal atrial fibrillation. A placebo-controlled double-blind study].

BACKGROUND: Atrial fibrillation is a relatively frequent atrial arrhythmias activated with increased morbidity and mortality. METHODS: To assess the propafenone and sotalol efficacy in the prevention of paroxysmal atrial fibrillation (FA) we enrolled, in a double blind placebo controlled study over 1 year, 300 patients (168 males); mean age 52.3 +/- 17.2 years, randomized to receive orally, three times daily, either propafenone (mean daily dose of 13 +/- 1.5 mg/Kg; Group A: 102 patients) or sotalol (mean daily dose of 3 +/- 0.4 mg/Kg; Group B: 106 patients) or placebo (Group C: 92 patients). All subjects experienced in previous 12 months at least 4 FA episodes. During follow-up we considered atrial tachyarrhythmia (TAA) onset: FA recurrences and/or the onset of atrial flutter (FIA). Three patients (3%) of Group A and 5 (5%) of Group B interrupted therapy for side effects; 5 patients (5.5%) of Group C with supraventricular tachycardia interrupted the double blind therapy; 11 were lost to follow-up. RESULTS: Of the remaining 276 patients, TAA were observed in 43 (44.8%) of 96 patients in Group A, 28 (29.5%) of 95 patients in Group B and 62 (72.9%) of 85 patients in Group C. TAA were significantly less in A and B groups than in Group C (p < 0.005); a significant TAA reduction was also observed in patients treated with sotalol compared with those treated with propafenone (p < 0.05). TAA were: FA-118 (88.7%) and FIA-15 (11.3%). The arrhythmia free time was significantly shorter in Group C. CONCLUSIONS: Sotalol seems to be more effective than propafenone and therefore represents a valid alternative for FA prevention.

Adult↗

Effectiveness of intravenous propafenone for conversion of recent-onset atrial fibrillation: a placebo-controlled study.

To evaluate the efficacy of propafenone in converting recent-onset atrial fibrillation (AF) lasting < 7 days, 182 patients were treated intravenously with propafenone (Group 1, n = 98) and with placebo 0.9% saline solution (Group 2, n = 84) in a double blind study. The treatment was continued until sinus rhythm (SR) was restored, but for no more than 24 h. Eighty-nine patients treated with propafenone (90.8%) and 27 patients treated with placebo (32.1%) responded to the treatment and SR was restored (p < 0.0005). The mean time for SR restoration was 2.51 +/- 2.77 h in Group 1, and 17.15 +/- 7.8 h in Group 2 (p < 0.0005). In both groups the patients in whom SR was not restored (nonresponders) had larger left atrial size and longer duration of AF than responders at the onset of the arrhythmia. Nonresponders in Group 1 showed a decrease in mean ventricular rate (MVR) from 143 +/- 16 to 101 +/- 18 (p < 0.0005), while in the nonresponders in Group 2 no reduction of MVR was observed. Two patients whose SR was restored with propafenone had sinus standstill lasting 3.4 and 3.8 s, respectively. Propafenone used intravenously is an effective, quick, and safe drug for treating AF. Moreover, it significantly reduces MVR in nonresponders.

Adult↗

[The efficacy of intravenous propafenone and amiodarone in the conversion of recent-onset atrial fibrillation. A 1-year follow-up with oral treatment].

One hundred and ninety-six patients with stable atrial fibrillation of recent onset received propafenone (98 patients) or Amiodarone (98 patients) intravenously. Eighty-nine subjects (90.8%) who received propafenone, and 79 patients (80.6%) who received amiodarone were converted to sinus rhythm (p > 0.05). The mean conversion time was 2.51 +/- 2.77 hours after propafenone and 11.21 +/- 4.32 hours after amiodarone (p < 0.0005). The same drug was continued per os in converted patients, and efficacy in maintaining sinus rhythm was evaluated in a one-year follow-up. Symptomatic atrial tachydysrhythmias were observed in 20 (22.4%) of the 89 patients treated with oral propafenone and in 12 (15.18%) of the 79 patients receiving oral amiodarone (p > 0.05). Conversion to sinus rhythm was affected by the duration of arrhythmia and by left atrial size, the latter determining sinus rhythm stability. Both drugs used intravenously are efficacious and safe. Propafenone showed a more rapid action. Oral treatment with low doses for long periods of time with both drugs showed neither important side effects nor proarrhythmic consequences, with satisfactory results.

Administration, Oral↗

[Cholesterol and vascular disease. Study of pravastatin ].

Variations in lipid profile and incidence of vascular events were evaluated. Group 1 had a 29.3% reduction of total and a 38.3% reduction of LDL cholesterol as against reductions of 9% and 9.6% respectively in group 2. No significant difference was observed between the two groups as far as the vascular events considered were concerned. Pravastatin is an effective and safe drug. The lack of influence on the evolution of vascular disease would appear to be correlated to the small number of subjects studied and the short follow-up.

Adult↗

[Serum osteocalcin and diabetes mellitus. A study of 98 patients].

The goal of this study was to evaluate in 98 diabetic patients the serum levels of osteocalcin (OC) and their relationship with glycosylated hemoglobin levels and with the duration, calculated in years, of the disease. Patients were divided in 3 groups: 17 IDDM patients, 62 NIDDM patients treated with oral hypoglycaemic agents, and 19 NIDDM patients treated with insulin. Results were compared to 2 different control groups. In IDDM patients OC serum levels were significantly lower if compared either to control group and to NIDDM patients. The 2 groups of NIDDM patients showed significantly higher OC values than controls. No significant relationship resulted between OC levels, the duration of diabetes and the glycosylated hemoglobin values. The results of the study indicate a direct correlation between pancreatic function and osteoblastic activity: insulin lack is associated with reduced OC serum levels.

Adolescent↗

[The benefits of L-carnitine therapy in essential arterial hypertension with diabetes mellitus type II].

Carnitine is a natural substance essential for the mitochondrial oxidation of long-chain fatty acids and therefore regulates the energy metabolism of the cells. Tissue carnitine levels are altered under diabetes mellitus or hypertension. The aim of this study was to evaluate the efficacy and tolerability of L-carnitine therapy in essential hypertension with diabetes mellitus type II. A clinical trial was performed in two homogeneous groups with essential hypertension and diabetes mellitus type II. L-carnitine was given orally, 2 g twice daily, for 45 weeks. In the group of patients treated with L-carnitine in comparison with control group cardiac arrhythmias, chiefly extrasystoles, some disorders of A-V conduction and some electrocardiographic signs of ischaemia stopped or diminished and symptoms, chiefly asthenia, significantly improved. No side effects were observed during the treatment. These results show that treatment with L-carnitine is useful and well tolerated in patients with essential hypertension and diabetes mellitus type II.

Aged↗